MedTrace Logo

Biological Response of Stage IV Knee Osteoarthritis to Serial 12.5% Dextrose

NCT01210183 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2014-05-20

No results posted yet for this study

Summary

Dextrose injection in end-stage knee arthritis will cause growth of cartilage cells in a particular area of complete cartilage loss. Dextrose concentration will be 12.5%. Cartilage status will be monitored by pre and post treatment arthroscopy views with specialized (methylene blue) staining for cartilage.

Conditions

Interventions

DRUG

Dextrose intraarticularly administered

9 ml of 12.5% dextrose

Sponsors & Collaborators

  • Universidad Nacional de Rosario

    lead OTHER

Principal Investigators

  • Gaston A Topol, M.D. · Hospital Provincial de Rosario

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • Argentina

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01210183 on ClinicalTrials.gov